Cost effectiveness analysis of CAR-T cell therapy for patients with relapsed/refractory multiple myeloma in China

References

• Cowan AJ, Allen C, Barac A, et al. Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016. JAMA Oncol. 2018;4(9):1221–1227.
   PubMed Web of Science ®Google Scholar
• Michels TC, Petersen KE. Multiple myeloma: diagnosis and treatment. Am Fam Physician. 2017;95(6):373–383.
   PubMed Web of Science ®Google Scholar
• Martin T, Huff CA. Multiple myeloma: current advances and future directions. Clin Lymphoma Myeloma Leuk. 2019;19(5):255–263.
   PubMed Web of Science ®Google Scholar
• Bazarbachi AH, Al Hamed R, Malard F, et al. Relapsed refractory multiple myeloma: a comprehensive overview. Leukemia. 2019;33(10):2343–2357.
   PubMed Web of Science ®Google Scholar
• Yang Y, Li Y, Gu H, et al. Emerging agents and regimens for multiple myeloma. J Hematol Oncol. 2020;13(1):150.
   PubMed Web of Science ®Google Scholar
• Joseph NS, Tai YT, Anderson KC, et al. Novel approaches to treating relapsed and refractory multiple myeloma with a focus on recent approvals of Belantamab Mafodotin and selinexor. Clin Pharmacol. 2021;13:169–180.
   PubMed Web of Science ®Google Scholar
• Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR-T cells. Nat Rev Cancer. 2021;21(3):145–161.
   PubMed Web of Science ®Google Scholar
• MacKay M, Afshinnekoo E, Rub J, et al. The therapeutic landscape for cells engineered with chimeric antigen receptors. Nat Biotechnol. 2020;38(2):233–244.
   PubMed Web of Science ®Google Scholar
• June CH, O’Connor RS, Kawalekar OU, et al. CAR-T cell immunotherapy for human cancer. Science. 2018;359(6382):1361–1365.
   PubMed Web of Science ®Google Scholar
• Celgene Corporation, a Bristol-Myers Squibb Company: ABECMA® (idecabtagene vicleucel) prescribing information. https://packageinserts.bms.co-m/pi/pi_abecma.pdf.
   Google Scholar
• Janssen Biotech, Inc and Legend Biotech: CARVYKTI® (ciltacabtagene autoleucel) prescribing information. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/CARVYKTI-pi.pdf.
   Google Scholar
• Munshi NC, Anderson LD, Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705–716.
   PubMed Web of Science ®Google Scholar
• Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2023;41(6):1265–1274.
   PubMed Web of Science ®Google Scholar
• Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266–2275.
   PubMed Web of Science ®Google Scholar
• Lin JK, Muffly LS, Spinner MA, et al. Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-Cell lymphoma. J Clin Oncol. 2019;37(24):2105–2119.
   PubMed Web of Science ®Google Scholar
• Whittington MD, McQueen RB, Ollendorf DA, et al. Long-term survival and value of chimeric antigen receptor T-Cell therapy for pediatric patients with relapsed or refractory leukemia. JAMA Pediatr. 2018;172(12):1161–1168.
   PubMed Web of Science ®Google Scholar
• Furzer J, Gupta S, Nathan PC, et al. Cost-effectiveness of tisagenlecleucel vs standard care in high-risk relapsed pediatric acute lymphoblastic leukemia in Canada. JAMA Oncol. 2020;6(3):393–401.
   PubMed Web of Science ®Google Scholar
• Moradi-Lakeh M, Yaghoubi M, Seitz P, et al. Cost-Effectiveness of tisagenlecleucel in paediatric acute lymphoblastic leukaemia (pALL) and adult diffuse large B-Cell lymphoma (DLBCL) in Switzerland. Adv Ther. 2021;38(6):3427–3443.
   PubMed Web of Science ®Google Scholar
• Cher BP, Gan KY, Aziz MIA, et al. Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma from Singapore’s healthcare system perspective. J Med Econ. 2020;23(11):1321–1329.
   PubMed Web of Science ®Google Scholar
• Ribera Santasusana JM, de Andrés Saldaña A, García-Muñoz N, et al. Cost-Effectiveness analysis of tisagenlecleucel in the treatment of relapsed or refractory B-Cell acute lymphoblastic leukaemia in children and young adults in Spain. Clinicoecon Outcomes Res. 2020;12:253–264.
   PubMed Web of Science ®Google Scholar
• Wakase S, Teshima T, Zhang J, et al. Cost-Effectiveness analysis of tisagenlecleucel for the treatment of pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia in Japan. Transplant Cell Ther. 2021;27(3):241.e1–241.e11.
   PubMedGoogle Scholar
• Diaby V, Adunlin G, Montero AJ. Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial. Pharmacoeconomics. 2014;32(2):101–108.
   PubMed Web of Science ®Google Scholar
• Liu N, Zhou Y, Lee JJ. IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2021;21(1):111.
   PubMed Web of Science ®Google Scholar
• Guyot P, Ades A, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12(1):9.
   PubMed Web of Science ®Google Scholar
• Raje NS, Siegel DS, Jagannath S, et al. 3234 Idecabtagene vicleucel (ide-cel, bb2121) in relapsed and refractory multiple myeloma: analyses of high-risk subgroups in the KarMMa Study. ASH; December 7, 2020, 2020.
   Google Scholar
• Wang B, Liu J, Zhao W-H, et al. 2304 Chimeric Antigen Receptor T cell therapy in the relapsed or refractory multiple myeloma with extramedullary disease–a single institution observation in China. ASH; December 6, 2020, 2020.
   Google Scholar
• Binder M, Nandakumar B, Rajkumar SV, et al. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. Leukemia. 2022;36(3):801–808.
   PubMed Web of Science ®Google Scholar
• Clinical trial: Clinical and basic research on BCMA-CAR T cells in the treatment of multiple myeloma, ChiCTR1800017404. http://www.chictr.org.cn/showproj.aspx?proj=28864.
   Google Scholar
• Zhejiang Provincial Center for Drug&Medical Device Procurement, https://www.zjyxcg.cn/?pageNow=88.
   Google Scholar
• Li Z, Pan Z, Zhang L, et al. End-of-life cost and its determinants for cancer patients in urban China: a population-based retrospective study. BMJ Open. 2019;9(3):e026309.
   PubMed Web of Science ®Google Scholar
• Delforge M, Shah N, Rodriguez-Otero P, et al. 3465 Health state utility valuation in patients with triple-class-exposed relapsed and refractory multiple myeloma treated with the BCMA-Directed CAR T cell therapy, idecabtagene vicleucel (ide-cel, bb2121): results from the KarMMa trial. Blood. 2020;136(Supplement 1):14–15.
   Google Scholar
• Liu GG, Wu H, Li M, et al. Chinese time trade-off values for EQ-5D health states. Value Health. 2014;17(5):597–604.
   PubMed Web of Science ®Google Scholar
• Li X, Liu J, Chen M, et al. Health-related quality of life of patients with multiple myeloma: a real-world study in China. Cancer Med. 2020;9(21):7896–7913.
   PubMed Web of Science ®Google Scholar
• Yang Z, Busschbach J, Liu G, et al. EQ-5D-5L norms for the urban Chinese population in China. Health Qual Life Outcomes. 2018;16(1):210.
   PubMedGoogle Scholar
• Beinfeld M, Lee S, McQueen B, et al. Anti B-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pretreated relapsed and refractory multiple myeloma. J Manag Care Spec Pharm. 2021;27(9):1315–1320.
   PubMed Web of Science ®Google Scholar
• Sarkar RR, Gloude NJ, Schiff D, et al. Cost-effectiveness of chimeric antigen receptor T-cell therapy in pediatric relapsed/refractory B-Cell acute lymphoblastic leukemia. J Natl Cancer Inst. 2019;111(7):719–726.
   PubMedGoogle Scholar
• Rui M, Shi F, Shang Y, et al. Economic evaluation of cisplatin plus gemcitabine versus paclitaxel plus gemcitabine for the treatment of First-Line advanced metastatic Triple-Negative breast cancer in China: using markov model and partitioned survival model. Adv Ther. 2020;37(9):3761–3774.
   PubMed Web of Science ®Google Scholar
• Rui M, Wang Y, Fei Z, et al. Will the markov model and partitioned survival model lead to different results? A review of recent economic evidence of cancer treatments. Expert Rev Pharmacoecon Outcomes Res. 2021;21(3):373–380.
   PubMed Web of Science ®Google Scholar
• Robinson LA, Hammitt JK, Chang AY, et al. Understanding and improving the one- and three-times GDP per capita cost-effectiveness thresholds. Health Policy Plan. 2017;32(1):141–145.
   PubMed Web of Science ®Google Scholar
• Marseille E, Larson B, Kazi DS, et al. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015;93(2):118–124.
   PubMed Web of Science ®Google Scholar
• Cai D, Shi S, Jiang S, et al. Estimation of the cost-effective threshold of a quality-adjusted life year in China based on the value of statistical life. Eur J Health Econ. 2022;23(4):607–615.
   PubMed Web of Science ®Google Scholar
• Ochalek J, Wang H, Gu Y, et al. Informing a cost-effectiveness threshold for health technology assessment in China: a marginal productivity approach. Pharmacoeconomics. 2020;38(12):1319–1331.
   PubMed Web of Science ®Google Scholar